<DOC>
	<DOCNO>NCT00652158</DOCNO>
	<brief_summary>This phase 1 clinical trial design evaluate increase duration MLN8054 oral dosing patient advanced malignancy . MLN8054 give daily 4 7 consecutive day per week 2 3 week . Following 2- 3-week treatment period 2 week recovery period .</brief_summary>
	<brief_title>A Phase 1 Trial Extended MLN8054 Dosing Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Has histologically cytologically confirm metastatic and/or advance malignancy ( include lymphoma exclude malignancy extensive bone marrow involvement leukemia multiple myeloma ) standard treatment offer curative lifeprolonging potential Aged 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Expected survival longer 3 month enrollment study Radiographically clinically evaluable tumor ; however , measurable disease require participation study Suitable venous access conduct blood sample determination MLN8054 plasma concentration Willingness serial skin punch biopsy obtain , feasible , serial biopsy tumor tissue obtain follow first dose MLN8054 Note : Once relationship drug exposure inhibition Aurora A kinase activity establish , patient subsequently enrol study require undergo either tumor skin biopsy . 8 . Recovered reversible effect prior antineoplastic therapy least 4 week elapse since last exposure cytotoxic chemotherapy radiotherapy least 6 week elapse since exposure nitrosoureas mitomycin C. Patients treat fully human monoclonal antibody must receive treatment antibody least 6 week , treat chimeric monoclonal antibody must receive treatment antibody least 4 week . Patients treat noncytotoxic small molecule drug ( eg , tyrosine kinase inhibitor Tarceva hormonal agent Femara® ) must receive treatment drug least 2 week first dose MLN8054 give . Male patient must use appropriate method barrier contraception ( ie , condom ) inform sexual partner must also use reliable method contraception ( eg , hormonal contraceptive , intrauterine device , diaphragm spermicide ) study 3 month last dose study treatment . Female patient must postmenopausal , surgically sterilize , willing use reliable method birth control ( eg , hormonal contraceptive , intrauterine device , diaphragm spermicide , abstinence ) study 3 month last dose study treatment . They inform male sexual partner use appropriate method barrier contraception ( ie , condom ) well . Able give inform consent conduct studyrelated procedure part normal medical care able comply protocol Patients meeting follow exclusion criterion enrol study : Pregnant lactate Major surgery within 21 day precede first dose study treatment Infection require antibiotic therapy within 7 day precede first dose study treatment Lifethreatening illness unrelated cancer Ongoing nausea vomit great Grade 1 severity . Patients require ongoing treatment metoclopramide control nausea vomiting , point Grade 1 less severity , allow participate trial . Diarrhea great Grade 1 severity . Patients require ongoing therapy antimotility agent control diarrhea Grade 1 low level allow participate trial . Known GI disease could interfere oral absorption tolerance MLN8054 Difficulty swallow capsule Inability remain nothing mouth ( NPO ) , except water prescribe medication , 2 hour precede 2 hour follow dose MLN8054 Received 4 previous cytotoxic chemotherapeutic regimen include regimen use adjuvant neoadjuvant therapy . There limit number noncytotoxic therapy ( eg , hormonal immunologic ) patient may receive . Tyrosine kinase inhibitor ( eg , Tarceva Iressa® ) consider noncytotoxic compound . Prior treatment highdose chemotherapy , define chemotherapy require use peripheral blood bone marrow stem cell support hematopoietic reconstitution Prior treatment radiation therapy involve great equal 25 % hematopoietically active bone marrow Clinical and/or radiographic evidence cerebral metastasis . However , patient history CNS metastasis radiographic clinical evidence residual tumor ( eg , follow complete surgical resection ) exclude participation study . Absolute neutrophil count &lt; 1.5 x 106/ul ; platelet count &lt; 100 x 106/ul . Serum creatinine &gt; 1.6 mg/dL measure estimate ( CockcroftGault formula ) creatinine clearance &lt; 30 mL/minute Bilirubin &gt; 1.25 time upper limit normal range ( ULN ) ; aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2 time ULN , alkaline phosphatase ( ALP ) &gt; 2 time ULN . Both AST ALP may elevate 5 time ULN elevation reasonably ascribe presence metastatic disease liver and/or bone ; however , ALT must circumstance &lt; 2 time ULN . Abnormalities arrhythmias 12lead electrocardiogram ( ECG ) , opinion investigator , consider clinically significant Known suspect human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status know suspect active hepatitis C infection Known suspect disorder bilirubin metabolism excretion include , limited , Gilbert 's syndrome , CriglerNajjar syndrome , DubinJohnson syndrome , Rotor syndrome Inclusion trial investigational drug previous 4 week Admission alcohol abuse inability restrict consumption alcohol 1 standard unit alcohol per day study 21 day last dose study treatment . A standard unit alcohol define one 12 oz beer , 1.5 oz 80 proof alcohol , one 6 oz glass wine . Note : criterion 22 , 23 , 24 apply patient biopsy tumor tissue plan . aPTT and/or PT exceed ULN Known bleed diathesis history abnormal bleeding Ongoing therapy anticoagulant ( eg , aspirin , plavix , coumadin , heparin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>